Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients.
about
Lung transplantation at DukeThe Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant RecipientsAntibody desensitization therapy in highly sensitized lung transplant candidates.Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: Does it work?What's new in clinical solid organ transplantation by 2013.The impact of pre-transplant allosensitization on outcomes after lung transplantation.Reduced Cerebral Perfusion Pressure during Lung Transplant Surgery Is Associated with Risk, Duration, and Severity of Postoperative Delirium.Validation and Refinement of Chronic Lung Allograft Dysfunction Phenotypes in Bilateral and Single Lung Recipients.CXCR3 ligands are associated with the continuum of diffuse alveolar damage to chronic lung allograft dysfunction.Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction.Current views on chronic rejection after lung transplantation.Immunological diversity in phenotypes of chronic lung allograft dysfunction: a comprehensive immunohistochemical analysis.Comprehensive Care of the Lung Transplant Patient.Immune Responses to Tissue-Restricted Nonmajor Histocompatibility Complex Antigens in Allograft RejectionAntibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.Lung Injury Combined with Loss of Regulatory T Cells Leads to De Novo Lung-Restricted Autoimmunity.Long-Term Persistence of Donor Alveolar Macrophages in Human Lung Transplant Recipients That Influences Donor-Specific Immune Responses.IgM-Enriched Human Intravenous Immunoglobulin-Based Treatment of Patients With Early Donor Specific Anti-HLA Antibodies After Lung Transplantation.Outside-in HLA class I signaling regulates ICAM-1 clustering and endothelial cell-monocyte interactions via mTOR in transplant antibody-mediated rejection.Prevention of chronic rejection after lung transplantation.Acute rejection.Depressive symptoms and early mortality following lung transplantation: A pilot study.Human Leukocyte Antigen Sensitization in Solid Organ Transplantation: A Primer on Terminology, Testing, and Clinical Significance for the Apheresis Practitioner.Detection and clinical impact of human leukocyte antigen antibodies in lung transplantation: A systematic review and meta-analysis.HLA Matching at the Eplet Level Protects Against Chronic Lung Allograft Dysfunction.Survival in sensitized lung transplant recipients with perioperative desensitization.De novo donor-specific HLA antibodies: biomarkers of pancreas transplant failure.
P2860
Q26748519-9BB97EE6-C663-4FA9-B473-693AC3D69AECQ26774993-573BCF25-B6E0-4325-B076-49F5C6B7FE9DQ33414196-9BB85172-5B4A-495F-9F99-15E2C5665C3CQ33437712-E2EC146E-93DA-450C-BB20-5156F3AD5093Q34761349-B97F3D21-F9B0-4174-B3B2-33E8A03D5F03Q36202595-DD9916F5-B257-40B3-AA27-B844D2ED4CC3Q37241531-A661F5E8-F280-43D9-BFC5-CCEC27B5B3FFQ37247946-DCB63A34-AF54-4834-A7F7-6783FBB2EF39Q37393663-BFB72E70-9D42-4FCF-B2A1-583898F0E924Q37698328-15E83453-EAF5-4183-B8A9-E3C6FA0A9B0DQ38413323-40F03CB8-186B-4544-A683-0AD9F7B1971FQ38785330-653A98AF-4BD7-410F-9157-63F2C05DF44AQ38978203-78673042-7CB9-489B-BC43-9F19C6D8615DQ39121365-086C4C81-60CF-49A7-B661-A63956CD2526Q39366396-2D40148C-C70D-4C34-8103-061039B5C517Q39402829-F68DBC2F-35FC-4881-B33E-CB8F972290CAQ39928595-B49F1DDB-735C-4D87-BCAA-3DCC4CCA4E98Q40293836-38C4B7BF-EFBB-4FCE-880F-06E4C7E23F46Q40668499-75420106-3D50-4B0E-8E2F-7C78CD28C42FQ42324374-D2B50232-7846-4D78-A476-6B872E4CA639Q42364236-314372C4-F784-4E79-B4A0-54A8EF3E48B5Q46258296-7274C9E4-4C19-43A3-9740-1C4F70EB4EAAQ47662940-32DD769E-6F50-44B9-87F3-8243D682204CQ47744928-49B91EFE-A657-475F-80E1-AEEF06F1436DQ48032372-01CF7526-E470-4DDC-818B-AA83FA390944Q48112929-11F4B358-F512-46AD-AB1E-62D7C00A2837Q48231169-B395ABDF-4315-455D-A51B-6FFB9E2E3AF9Q50247563-B82714CA-FCEE-40DA-836A-5F298B76CBEAQ51015580-F0DB1820-B277-4D01-863A-80310C6F0718Q53851101-27FC5B35-9367-4882-B6F1-271F73E12685
P2860
Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Implications for human leukocy ...... ar experience in 441 patients.
@en
type
label
Implications for human leukocy ...... ar experience in 441 patients.
@en
prefLabel
Implications for human leukocy ...... ar experience in 441 patients.
@en
P2093
P2860
P356
P1433
P1476
Implications for human leukocy ...... ear experience in 441 patients
@en
P2093
C Ashley Finlen-Copeland
David W Zaas
Dong-Feng Chen
Nancy L Reinsmoen
Scott M Palmer
W Austin Davis
Ziwei Wang
P2860
P304
P356
10.1378/CHEST.12-0587
P407
P577
2013-07-01T00:00:00Z